During the past decade, Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 9 clinical trials were completed, i.e. on average, 128.6% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center" #1 sponsor was "Matthew Galsky" with 4 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Hoosier Cancer Research Network" with 2 trials sponsored, "Cancer Insight, LLC" with 1 trials sponsored and "Dragonfly Therapeutics" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center" #1 collaborator was "Bristol-Myers Squibb" with 3 trials as a collaborator, "Hoosier Cancer Research Network" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Sellas Life Sciences Group" with 2 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center" are "Bladder Cancer" (4 trials), "Urothelial Carcinoma" (4 trials), "Breast Cancer" (2 trials), "Advanced Soft Tissue Sarcoma" (1 trials) and "Bladder Carcinoma" (1 trials). Many other conditions were trialed in "Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center" in a lesser frequency.

Most popular intervention types in "Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center" are "Drug" (16 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (5 trials), "Atezolizumab" (3 trials), "Cisplatin" (3 trials), "Nivolumab" (3 trials) and "Placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center" are 15 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, 4 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".